SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Trousseau A. Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris, 3rd edition. Paris: J-B. Balliere et Fils, 1865: 654712.
  • 2
    Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am. J. Clin. Pathol. 1987; 88: 596602.
  • 3
    Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992; 18: 353372.
  • 4
    Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am. 1996; 10: 457484.
  • 5
    Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trosseau's syndrome revisited. Blood. 1983; 62: 1431.
  • 6
    Kwaan HC, Keer HN. Fibrinolysis and cancer. Semin Thromb Hemost. 1990; 16: 230235.
  • 7
    Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost. 1999; 25: 167172.
  • 8
    Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornestein DL. Clotting factors in tumor tissue: implications for cancer therapy. Blood Coagul Fibrinolysis. 1990; 1: 7178.
  • 9
    Lebeau B, Chastang C, Brechot J-M, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 1994; 74: 3845.
  • 10
    Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 1989; 7: 9931002.
  • 11
    Wojtukiewicz MZ, Zacharski LR, Moritz DM, Edwards RL, Rickles FR. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinolysis. 1992; 3: 429437.
  • 12
    Seitz R, Rappe N, Kraus M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis. 1993; 4: 249254.
  • 13
    Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S. Evaluating prethrombotic state in lung cancer using molecular markers. Chest. 1993; 103: 196200.
  • 14
    Gabazza EC, Taguchi O, Yamakami T, et al. Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer. Eur J Cancer. 1994; 30A: 12761281.
  • 15
    Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997; 52: 563565.
  • 16
    Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications [see comments]. Eur J Cancer. 1997; 33: 5055.
  • 17
    Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001; 17: 667673.
  • 18
    Junker K. Prognostic factors in Stage I/II non-small cell lung cancer. Lung Cancer. 2001; 33 (Suppl 1): S17S24.
  • 19
    World Health Organization. International histological classification of tumours. Berlin: Springer-Verlag, 1991.
  • 20
    Mountain CF. Revisions in the International System for Staging Lung Cancer [see comments]. Chest. 1997; 111: 17101717.
  • 21
    Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000; 117: 12471255.
  • 22
    Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacleodCM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949: 199205.
  • 23
    Buccheri GF, Violante B, Sartoris AM, Ferrigno D, Curcio A, Vola F. Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer. 1986; 57: 23892396.
  • 24
    Buccheri GF, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer. 1987; 60: 4250.
  • 25
    Buccheri G. Chemotherapy and survival in non-small cell lung cancer. The old vexata questio. Chest. 1991; 99: 13281329.
  • 26
    Siegel S. Nonparametric statistics for the behavioral sciences. New York: MacGraw Hill, 1956.
  • 27
    Kaplan EL, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 58: 457481.
  • 28
    SAS Institute Inc. SAS/STAT user guide [computer program]. Cary, NC: SAS Institute Inc., 2000.
  • 29
    Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. Br J Cancer. 1977; 35: 139.
  • 30
    Cox DR. Regression models and life tables. J R Statist Soc. 1972; 34: 187220.
  • 31
    McCullaghRJ, NelderJA, editors. Generalized linear models. Cambridge: Chapman and Hall University Press, 1988.
  • 32
    Francis CW, Marder VJ. Mechanism of fibrinolysis. In: CollerB, editor. Williams hematology (5th edition). New York: McGraw-Hill, 1995: 12521260.
  • 33
    Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002; 86: 389395.
  • 34
    Ho CH, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol Oncol. 1999; 75: 397400.
  • 35
    Mirshahi SS, Pujade-Lauraine E, Soria C, et al. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment. Cancer. 1992; 69: 22892292.
  • 36
    Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001; 31: 388394.
  • 37
    Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today. 1998; 28: 373378.
  • 38
    Rella C, Coviello M, De Frenza N, et al. Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125. Tumori. 1993; 79: 347351.
  • 39
    Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001; 12: 5158.